07:00 , Jun 1, 2015 |  BC Week In Review  |  Company News

Astellas musculoskeletal, ophthalmic news

Astellas released a three-year strategic plan that adds muscle disease and ophthalmology therapeutic areas. The company’s innovative medicines strategy for FY15-17 also will include development of next-generation vaccines and cell therapies to treat cardiovascular disease...
01:47 , May 28, 2015 |  BC Extra  |  Company News

Astellas adds muscle disease, ophthalmology TAs

Astellas Pharma Inc. (Tokyo:4503) released a new three-year strategic plan that adds muscle diseases and ophthalmology as therapeutic areas. The company's innovative medicines strategy for FY15-17 also will include development of next-generation vaccines and cell...
08:00 , Feb 11, 2013 |  BC Week In Review  |  Clinical News

ASP8232: Phase I started

Astellas said in its 3Q12 earnings ending Dec. 31, 2012, that it began a Phase I trial of ASP8232. Astellas Pharma Inc. (Tokyo:4503), Tokyo, Japan   Product: ASP8232   Business: Renal   Molecular target: NA...